Boston Scientific launches a clinical trial of its Vessix renal denervation device in treating hypertension, aiming to separate its effects from drug therapy for high blood pressure.
ReCor Medical raises a $15 million Series D financing for a planned U.S. study of its ultrasound renal denervation device.
A Japanese healthcare conglomerate is the lead investor ReCor Medical's $15 million Series D round ReCor plans to use to back a U.S. clinical trial of its ultrasound renal denervation device.
Medtronic launches a new clinical trial examining renal denervation as a treatment for hypertension, aiming to settle the 'confounding factors' that led to the failure of its Symplicity-3 trial.
Medtronic is taking another shot at renal denervation to treat drug-resistant hypertension, a year after a pivotal trial for its key product in the space failed to meet its efficacy endpoint.
Verve Medical raises just less than $2 million in an equity offering for its renal denervation device.
Stealthy renal denervation startup Verve Medical raised close to $2 million, according to a regulatory filing, with funding likely slated to help support clinical trials.
Rox Medical's stent-like Coupler implant, designed to treat resistant hypertension, fares well in a pivotal trial as the company gears up for a run at an investigational device exemption from the FDA.
Vascular Dynamics secures a $17 million Series B round to fund clinical trials for its device to treat drug-resistant hypertension.
Vascular Dynamics said it secured $16.85 million in Series B financing to fund clinical trials for its device to treat drug-resistant hypertension.